Baidu
map

Lancet Psychiatry:精神病患者持续服用大麻的用药依从性及复发风险

2017-07-11 zhangfan MedSci原创

研究发现20-36%大麻持续使用的精神病不良影响结果是通过服药依从性作用介导的。服药依从性干预可以部分缓解大麻使用的精神危害

研究发现使用大麻后导致的精神病复发可能与抗精神病药物非依从性相关。近日研究考察了与大麻使用有关的不良结果与药物依从性之间的关系。

本次研究的数据来自4个伦敦精神疾病医院的成人住院和门诊患者以及精神健康国民保健服务信托基金,对245例首发精神病患者进行2年的随访并考察患者精神病发病后大麻使用情况。根据WHO生活史图表记录患者复发情况并依此评估药物依从性。根据ICD-10诊断标准评估精神病发作情况。采用结构方程模型分析判断药物依从性与持续使用大麻对复发风险的影响。研究主要终点是复发,定义为2年内精神疾病治疗后症状加重。

在研究期间共397名患者首次精神病发作。随访的397例患者中,有133例拒绝参加研究,19例由于缺少数据而无法纳入。245名患者中有91人(37%)在2年的随访期间复发。持续使用大麻的预测预后较差,包括复发,复发次数、复发和护理时间,强度以及后续行动。控制结构方程模型分析,药物依从性的部分介导了持续使用大麻对结果的影响,包括复发的风险 (比例调节=26%, β间接影响=0·08, 95% ,CI 0.004-0.16),复发次数 (36%, β间接影响=0.07, 0.003-0.14),直到复发时间 (28%, β间接影响=-0.26, -0.53-0.001), 护理强度(20%, β间接影响=0.06, 0.004-0.11),但不影响疾病复发后病程 (6%, β间接影响=0.03, -0.03-0.09)。调整后的发现复发风险(R2 = 0.25),复发次数(R2 = 0.21)、复发时间(R2 = 0.07),直到复发时间(R2 = 0.08),护理强度指数(R2 = 0.15)的方差适中。

研究发现20-36%大麻持续使用的精神病不良影响结果是通过服药依从性作用介导的。服药依从性干预可以部分缓解大麻使用的精神危害。

原始出处:

Tabea Schoeler et al. Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. Lancet Psychiatry. July 10 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1792064, encodeId=7d731e9206400, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Oct 20 06:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905470, encodeId=dd2a19054e083, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Dec 24 06:45:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042453, encodeId=93b12042453c0, content=<a href='/topic/show?id=d728e65519c' target=_blank style='color:#2F92EE;'>#精神病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76551, encryptionId=d728e65519c, topicName=精神病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7c9348, createdName=neizongke, createdTime=Mon Oct 30 16:45:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829076, encodeId=78da18290e6d0, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Feb 17 16:45:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272697, encodeId=fd5412e269778, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Wed Jul 12 23:45:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319288, encodeId=27cf131928851, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 12 23:45:00 CST 2017, time=2017-07-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1792064, encodeId=7d731e9206400, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Oct 20 06:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905470, encodeId=dd2a19054e083, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Dec 24 06:45:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042453, encodeId=93b12042453c0, content=<a href='/topic/show?id=d728e65519c' target=_blank style='color:#2F92EE;'>#精神病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76551, encryptionId=d728e65519c, topicName=精神病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7c9348, createdName=neizongke, createdTime=Mon Oct 30 16:45:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829076, encodeId=78da18290e6d0, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Feb 17 16:45:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272697, encodeId=fd5412e269778, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Wed Jul 12 23:45:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319288, encodeId=27cf131928851, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 12 23:45:00 CST 2017, time=2017-07-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1792064, encodeId=7d731e9206400, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Oct 20 06:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905470, encodeId=dd2a19054e083, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Dec 24 06:45:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042453, encodeId=93b12042453c0, content=<a href='/topic/show?id=d728e65519c' target=_blank style='color:#2F92EE;'>#精神病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76551, encryptionId=d728e65519c, topicName=精神病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7c9348, createdName=neizongke, createdTime=Mon Oct 30 16:45:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829076, encodeId=78da18290e6d0, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Feb 17 16:45:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272697, encodeId=fd5412e269778, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Wed Jul 12 23:45:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319288, encodeId=27cf131928851, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 12 23:45:00 CST 2017, time=2017-07-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1792064, encodeId=7d731e9206400, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Oct 20 06:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905470, encodeId=dd2a19054e083, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Dec 24 06:45:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042453, encodeId=93b12042453c0, content=<a href='/topic/show?id=d728e65519c' target=_blank style='color:#2F92EE;'>#精神病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76551, encryptionId=d728e65519c, topicName=精神病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7c9348, createdName=neizongke, createdTime=Mon Oct 30 16:45:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829076, encodeId=78da18290e6d0, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Feb 17 16:45:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272697, encodeId=fd5412e269778, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Wed Jul 12 23:45:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319288, encodeId=27cf131928851, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 12 23:45:00 CST 2017, time=2017-07-12, status=1, ipAttribution=)]
    2018-02-17 howi
  5. [GetPortalCommentsPageByObjectIdResponse(id=1792064, encodeId=7d731e9206400, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Oct 20 06:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905470, encodeId=dd2a19054e083, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Dec 24 06:45:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042453, encodeId=93b12042453c0, content=<a href='/topic/show?id=d728e65519c' target=_blank style='color:#2F92EE;'>#精神病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76551, encryptionId=d728e65519c, topicName=精神病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7c9348, createdName=neizongke, createdTime=Mon Oct 30 16:45:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829076, encodeId=78da18290e6d0, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Feb 17 16:45:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272697, encodeId=fd5412e269778, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Wed Jul 12 23:45:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319288, encodeId=27cf131928851, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 12 23:45:00 CST 2017, time=2017-07-12, status=1, ipAttribution=)]
    2017-07-12 kcb069
  6. [GetPortalCommentsPageByObjectIdResponse(id=1792064, encodeId=7d731e9206400, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Fri Oct 20 06:45:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905470, encodeId=dd2a19054e083, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Dec 24 06:45:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042453, encodeId=93b12042453c0, content=<a href='/topic/show?id=d728e65519c' target=_blank style='color:#2F92EE;'>#精神病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76551, encryptionId=d728e65519c, topicName=精神病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7c9348, createdName=neizongke, createdTime=Mon Oct 30 16:45:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829076, encodeId=78da18290e6d0, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Feb 17 16:45:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272697, encodeId=fd5412e269778, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Wed Jul 12 23:45:00 CST 2017, time=2017-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319288, encodeId=27cf131928851, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 12 23:45:00 CST 2017, time=2017-07-12, status=1, ipAttribution=)]
    2017-07-12 fyxzlh

相关资讯

Lancet Psychiat:在精神病患者中实施禁烟政策会导致暴力事件增加吗?

禁烟政策对于保护健康消除健康不公平有重要作用。对于在精神病院全面开展禁烟政策的一个主要障碍是工作人员担心禁烟会导致暴力事件增加。

Lancet psychiat:精神病患者中艾滋、乙肝和丙肝的发病率研究

重度精神病会增加发病率和死亡率。在重度精神病患者中血源性病毒(BBVs)的患病风险增加。

Nat Genet:RBM12基因截断突变导致精神病

研究人员采用全基因组测序和长距离定位对一个冰岛家族进行研究,其中包括十个患有精神类疾病(精神分裂症,分裂情感性障碍或精神病性躁郁症)的个体。我们发现所有患病个体都携带RBM12(RNA结合基序蛋白12)上的c.2377G> T突变(P = 2.2×10-4),这是一个会导致RNA识别motif缺失并产生截短蛋白的无义突变。

JAMA Psychiatry:利拉鲁肽可降低抗精神病药导致的心血管风险

利拉鲁肽可显著改善服用氯氮平或奥氮平的精神病患者的糖耐量水平、体重和心脏代谢紊乱的病情

只有韩国人会得的精神病 医学界正式承认“火病”

最近韩国媒体一篇题为《只有韩国人才患的疾病》的新闻成为话题。文章称,世界上存在唯独韩国人才患的疾病,而美国精神医学学会也正式承认了该疾病。

Lancet oncol:精神病患者中艾滋、乙肝和丙肝的发病率和风险因子

精神病患者中艾滋、乙肝和丙肝的发病率和风险因子

Baidu
map
Baidu
map
Baidu
map